JSM 2005 Online Program

Abstract #304109

This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

The Program has labeled the meeting rooms with "letters" preceding the name of the room, designating in which facility the room is located:

Minneapolis Convention Center = “MCC” Hilton Minneapolis Hotel = “H” Hyatt Regency Minneapolis = “HY”

Back to main JSM 2005 Program page

Legend:

= Applied Session,

= Theme Session,

= Presenter

Activity Number:	91
Type:	Topic Contributed
Date/Time:	Monday, August 8, 2005 : 8:30 AM to 10:20 AM
Sponsor:	General Methodology
Abstract - #304109
Title:	Selecting Drug Combinations: Adaptive Approach
Author(s):	Vladimir Dragalin*+ and Valerii Fedorov
Companies:	GlaxoSmithKline and GlaxoSmithKline
Address:	1250 Collegeville Rd, Collegeville, PA, 19426-0989, United States
Keywords:	adaptive design ; drug combination ; optimal experimental design ; dose-finding ; optimal safe dose
Abstract:	A parametric model is considered for the joint probability of the efficacy-toxicity response as a function of two doses of the combined drugs. Based on fixed trial-specific standards of the minimum acceptable efficacy response rate and the maximum tolerated toxicity rate, the therapeutic region is defined as a region on the plane of available doses of the two combined drugs. The optimization problem is formulated as a maximization, within the therapeutic region, of the probability of positive efficacy response with nontoxicity as a function of the two doses. The proposed penalized adaptive design selects the successive dose combinations by maximizing the increment of information per cost unit given the current data. Great flexibility can be achieved by using a penalty function, tailored to the desired goal of the considered clinical trial. The design is shown by simulation to have a good performance finding the optimal safe drug combinations and allocating patients at or near dose combinations that are both safe and efficacious.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2005 program